Pancreatic ductal adenocarcinoma (PDAC) has long been called the "king of cancers"—the five-year survival rate for metastatic patients is less than 10%, and median overall survival with later-line chemotherapy in previously treated patients is typically only six to seven months. The results of the Phase 3 RASolute 302 trial (NCT06625320) have delivered a seismic shock to this nearly stagnant field.
How was the trial designed?
RASolute 302 is a global, randomized controlled Phase 3 clinical trial that enrolled patients with RAS-mutant metastatic pancreatic cancer who had already received first-line treatment. Participants were randomly assigned to either daraxonrasib (RMC-6236) monotherapy or investigator's choice of standard chemotherapy, with overall survival (OS) as the primary endpoint. Notably, this is the first time a RAS-targeted drug has demonstrated a survival benefit in a randomized controlled Phase 3 trial for pancreatic cancer.
Key data at a glance
Results showed that the daraxonrasib group had a median overall survival of 13.2 months, compared with 6.7 months in the chemotherapy group—nearly doubling survival and reducing the risk of death by about 60% (hazard ratio approximately 0.40). Progression-free survival (PFS) also extended from 3.6 months to 7.2 months. In the past decades, later-line treatment for pancreatic cancer has never seen an improvement of this magnitude.
In terms of safety, the most common adverse reactions with daraxonrasib were rash, diarrhea, and fatigue, mostly mild to moderate, with a lower rate of discontinuation due to side effects than the chemotherapy group. For advanced patients requiring long-term treatment, the oral formulation and manageable side effects mean a substantial difference in quality of life.
Why is this mechanism so important?
Daraxonrasib is a "RAS(ON) multi-selective inhibitor." Unlike first-generation drugs that only target the inactive state of KRAS G12C, it forms a tri-complex with intracellular chaperone proteins to directly trap RAS proteins in the "ON" state, thereby inhibiting multiple mutant subtypes such as G12D, G12V, and G12R—which are the predominant subtypes in pancreatic cancer. This explains why it can show broad activity across subtypes in pancreatic cancer, a cancer type with a KRAS mutation rate as high as 90%.
Currently, daraxonrasib is also being tested in later-line trials for lung cancer and colorectal cancer, with first-line studies combining it with chemotherapy or immunotherapy underway. For patients with RAS mutations, confirming the mutation subtype in genetic testing reports is the first step in evaluating treatment options.